Literature DB >> 1346274

The cumulative risk of AIDS as the CD4 lymphocyte count declines.

A N Phillips1, C A Lee, J Elford, G Janossy, P B Kernoff.   

Abstract

A method is proposed for assessing the cumulative risk of various AIDS-defining conditions as the CD4 lymphocyte count declines in HIV-infected individuals. The method is analogous to survival analysis but is based on the CD4 lymphocyte count rather than on time. Thus, the level to which the CD4 lymphocyte count has declined, rather than the length of time since seroconversion, is considered as an individual's survival interval. The survival interval may be censored (due to lack of follow-up) or treated as an interval to failure (if the individual develops AIDS). The Kaplan-Meier (product-limit) estimates, of the proportion of individuals developing AIDS before reaching a given low CD4 lymphocyte count, may be useful for determining when prophylactic treatment should begin.

Entities:  

Mesh:

Year:  1992        PMID: 1346274

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  4 in total

1.  Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Authors:  J V Chancellor; A M Hill; C A Sabin; K N Simpson; M Youle
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

2.  T cell activation and disease severity in HIV infection.

Authors:  M Mahalingam; M Peakman; E T Davies; A Pozniak; T J McManus; D Vergani
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

3.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10

4.  Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Authors:  Nikos Pantazis; Charles Morrison; Pauli N Amornkul; Charlotte Lewden; Robert A Salata; Albert Minga; Tsungai Chipato; Harold Jaffe; Shabir Lakhi; Etienne Karita; Kholoud Porter; Laurence Meyer; Giota Touloumi
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.